Veracyte Q3 2021 revenue $60.4M (+94% YoY); raises FY guidance to $210-218M

VERACYTE, INC.

2021-Q3 EPS reported -$0.97 revenue$152,178,000

Total revenue $60.4M, up 94% YoY; volume 20,972 tests (+79%).
Net loss $14.1M ($0.20 EPS) vs $4.1M loss Q3 2020; includes HalioDx costs.
Completed HalioDx acquisition for $321M; launched Percepta Nasal Swab and Decipher Bladder tests.
FY 2021 revenue guidance raised to $210-218M from $200-208M, implying 79-86% growth.
Cash $164M at quarter-end; operating cash used $1.4M incl. $3.9M acquisition expenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.